A Phase 2 interventional study of Roxadustat and Placebo in Chronic Kidney Disease and Anemia, sponsored by FibroGen. Completed at 34 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 2, and was the 1st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
This study's enrollment of 117 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 161 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
10 studies in Renal Insufficiency, Chronic by Kyntra Bio: none open now, none under way, none of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 10 studies in Renal Insufficiency, Chronic by Kyntra Bio, this one is the 8th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 2, and was the 1st registered.
Kyntra Bio’s Renal Insufficiency, Chronic studies by the year they started, since 2006.
1 of the studies testing roxadustat in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 10 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety, tolerability, and pharmacodynamic effects of different oral doses of roxadustat administered 2 times a week (BIW) or 3 times a week (TIW) for up to 4 weeks to participants with chronic kidney disease (CKD) not requiring dialysis.
This study in participants with CKD not requiring dialysis was conducted in 2 parts (designated Part 1 and Part 2). Part 1 evaluated roxadustat doses at 1.0 and 2.0 milligrams/kilograms (mg/kg). Part 2 evaluated roxadustat doses at 0.7, 1.5, and 2.0 mg/kg.
On 08 May 2007, the Food and Drug Administration (FDA) placed a clinical hold on the study until evaluation of a report of a death due to fulminant hepatic failure in a participant with CKD in a FibroGen-sponsored clinical trial of another hypoxia inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) (FG-2216) being investigated for treatment of anemia in participants with CKD and other diseases. The clinical hold resulted in early termination of Part 1 of the study. On 24 March 2008, the FDA lifted the clinical hold and Part 2 of this study started.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
Drug: Roxadustat
Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
Drug: Roxadustat
Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
Drug: Roxadustat
Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
Drug: Roxadustat
Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
Drug: Roxadustat
Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
Drug: Roxadustat
Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
Drug: Roxadustat
Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
Drug: Roxadustat
Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
Drug: Placebo
Capsule
Also known as: FG-4592
Capsule
Primary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Treatment Discontinuation (Parts 1 and 2 Combined)
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs defined as an AE beginning after first dose of study drug until 28 days after last dose of study drug or existing AEs that worsened after first dose of study drug until the participant's last study visit. Severe AEs defined as incapacitating, inability to perform usual activities. Drug-related TEAEs defined as TEAEs with possible, probable, or definite relationship to study drug. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 16 (End of Study (EoS])
Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Day 26-29 (End of Treatment)
Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline was defined as the mean of last 3 available values prior to the first dose.
Time frame: Baseline, End of Treatment (EoT) (Day 26 for TIW Dosing or Day 29 for BIW Dosing)
Co-Primary Efficacy Outcome Measure: Change From Baseline in Hb at Week 8 (2 Weeks of Follow Up)
Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline is defined as the mean of last 3 available values prior to the first dose.
Time frame: Baseline, Week 8 (2 Weeks of Follow Up)
Number of Participants With a Hemoglobin Response (Not Due to a RBC Transfusion or IV Iron Supplementation During Treatment)
Hb response defined as an increase in Hb from baseline by ≥1.0 g/dL (not due to red blood cell transfusion or IV iron supplementation during treatment). The baseline for Hb was defined as the mean of the last 3 available Hb values obtained prior to the first dose.
Time frame: Baseline up to Day 26-29 (EoT), up to Week 8 (2 weeks of follow up), and up to Week 16 (EoS, 4 weeks of follow up)
Plasma Roxadustat Concentration (Part 2)
Time frame: Predose on Days 3 (TIW dose groups) or 4 (BIW dose groups), 8, 15, 22, and 26 (TIW dose groups) or 29 (BIW dose groups)
Change From Baseline in Plasma Erythropoietin in Part 1 Participants at Day 26 or Day 29
Baseline is defined as the last value obtained prior to the first dose.
Time frame: Baseline (Day 1), 1, 2, 3, 4, 6, 8, 12, 18, 24, 48, and 72 hours on Day 26 (TIW Dosing) or Day 29 (BIW Dosing)
Change From Baseline in Plasma Erythropoietin in Part 2 Participants at 4, 8, 12, and 24 Hours on Day 1
Baseline is defined as the last value obtained prior to the first dose.
Time frame: Baseline, 4, 8, 12, and 24 hours on Day 1
| Milestone | Roxadustat 0.7 Milligrams/Kilograms (mg/kg) BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 12 | 10 | 0 | 0 | 1 | 2 | 10 |
| Safety population | 0 | 0 | 12 | 9 | 0 | 0 | 1 | 2 | 10 |
| Efficacy evaluable (ee) population | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 1 | 6 |
| Pharmacokinetic (pk) population | 0 | 0 | 5 | 3 | 0 | 0 | 1 | 2 | 0 |
| Completed | 0 | 0 | 8 | 4 | 0 | 0 | 0 | 1 | 9 |
| Not completed | 0 | 0 | 4 | 6 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 3 | 4 | 0 | 0 | 1 | 1 | 1 |
| Milestone | Roxadustat 0.7 Milligrams/Kilograms (mg/kg) BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 13 | 0 | 0 | 10 | 11 | 10 | 10 | 18 |
| Safety population | 10 | 13 | 0 | 0 | 10 | 11 | 10 | 10 | 18 |
| Ee population | 10 | 12 | 0 | 0 | 10 | 11 | 10 | 10 | 11 |
| Pk population | 10 | 13 | 0 | 0 | 10 | 11 | 10 | 10 | 0 |
| Completed | 10 | 13 | 0 | 0 | 10 | 11 | 10 | 10 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs defined as an AE beginning after first dose of study drug until 28 days after last dose of study drug or existing AEs that worsened after first dose of study drug until the participant's last study visit. Severe AEs defined as incapacitating, inability to perform usual activities. Drug-related TEAEs defined as TEAEs with possible, probable, or definite relationship to study drug. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Any TEAEs | 3 | 9 | 7 | 5 | 9 | 7 | 7 | 5 | 13 |
| Serious TEAEs | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Severe TEAEs | 0 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
| Drug-Related TEAEs | 1 | 2 | 2 | 1 | 3 | 3 | 3 | 1 | 3 |
| TEAEs Leading to Treatment Discontinuation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline was defined as the mean of last 3 available values prior to the first dose.
| g/dL | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 10.32 ± 0.678 | 10.03 ± 0.709 | 9.18 ± 0.600 | 10.35 ± 0.849 | 10.28 ± 0.551 | 10.08 ± 0.650 | 9.97 ± 0.430 | 9.93 ± 0.806 | 10.10 ± 0.616 |
| Change at Day 26-29 | 0.25 ± 0.849 | 0.60 ± 0.756 | 0.44 ± 0.781 | 0.21 ± 1.016 | 1.22 ± 1.112 | 1.65 ± 1.033 | 1.35 ± 0.577 | 1.75 ± 1.200 | -0.05 ± 0.500 |
Mean Hb change from baseline was analyzed by treatment group and study visit. Baseline is defined as the mean of last 3 available values prior to the first dose.
| g/dL | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 10.32 ± 0.678 | 10.03 ± 0.709 | 9.18 ± 0.600 | 10.35 ± 0.849 | 10.28 ± 0.551 | 10.08 ± 0.650 | 9.97 ± 0.430 | 9.93 ± 0.806 | 10.10 ± 0.616 |
| Change at Week 8 | 0.59 ± 0.808 | 0.24 ± 0.846 | 0.50 ± 0.356 | 0.05 ± 1.435 | 0.79 ± 0.916 | 1.31 ± 0.743 | 1.21 ± 0.656 | 1.52 ± 0.815 | 0.04 ± 0.684 |
Hb response defined as an increase in Hb from baseline by ≥1.0 g/dL (not due to red blood cell transfusion or IV iron supplementation during treatment). The baseline for Hb was defined as the mean of the last 3 available Hb values obtained prior to the first dose.
| Participants | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Day 26-29 | 1 | 6 | 1 | 1 | 8 | 10 | 7 | 9 | 3 |
| Week 8 | 5 | 7 | 3 | 2 | 8 | 10 | 9 | 11 | 6 |
| Week 16 | 7 | 7 | 3 | 2 | 9 | 10 | 9 | 11 | 8 |
| nanograms (ng)/milliliter (mL) | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW |
|---|---|---|---|---|---|---|
| Day 3 | — | 394.800 ± 723.156 | — | 260.027 ± 133.524 | — | 422.700 ± 148.529 |
| Day 4 | 28.596 ± 19.737 | — | 168.310 ± 174.426 | — | 283.067 ± 376.601 | — |
| Day 8 | 19.884 ± 18.858 | 203.535 ± 343.167 | 125.185 ± 223.124 | 168.955 ± 147.019 | 291.856 ± 376.910 | 297.500 ± 393.134 |
| Day 15 | 22.997 ± 18.442 | 195.483 ± 369.794 | 134.116 ± 269.890 | 247.945 ± 204.624 | 358.400 ± 491.898 | 175.570 ± 144.779 |
| Day 22 | 36.432 ± 33.587 | 153.903 ± 173.388 | 147.323 ± 235.302 | 163.100 ± 167.695 | 171.833 ± 138.575 | 239.600 ± 324.307 |
| Day 26 | — | 331.640 ± 435.773 | — | 223.140 ± 140.340 | — | 508.889 ± 295.228 |
| Day 29 | 14.332 ± 9.935 | — | 150.599 ± 233.871 | — | 193.622 ± 279.533 | — |
Baseline is defined as the last value obtained prior to the first dose.
| milli-international units (mIU)/mL | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|
| Day 1, Baseline | 13.46 ± 5.69 | 13.30 ± 6.59 | 9.00 ± NA | 8.50 ± 3.96 | 13.75 ± 4.53 |
| Change at Day 26, 1 Hour | — | -1.50 ± 1.41 | — | 0.00 ± NA | 0.17 ± 0.21 |
| Change at Day 26, 2 Hour | — | -0.85 ± 1.91 | — | -0.60 ± NA | 0.67 ± 1.47 |
| Change at Day 26, 3 Hour | — | -0.95 ± 1.34 | — | 2.30 ± NA | -1.27 ± 3.15 |
| Change at Day 26, 4 Hour | — | -0.45 ± 0.07 | — | 29.70 ± NA | 0.50 ± 4.24 |
| Change at Day 26, 6 Hour | — | 8.05 ± 11.81 | — | 132.80 ± NA | 0.33 ± 3.80 |
| Change at Day 26, 8 Hour | — | 57.95 ± 63.29 | — | 462.00 ± NA | 0.20 ± 1.18 |
| Change at Day 26, 12 Hour | — | 81.80 ± 81.03 | — | 492.00 ± NA | -1.30 ± 1.71 |
| Change at Day 26, 18 Hour | — | 37.30 ± 13.01 | — | 176.90 ± NA | 0.87 ± 1.07 |
| Change at Day 26, 24 Hour | — | 22.35 ± 19.73 | — | 33.90 ± NA | 2.60 ± 5.46 |
| Change at Day 26, 48 Hour | — | 0.55 ± 10.39 | — | -0.50 ± NA | -7.50 ± 2.40 |
| Change at Day 26, 72 Hour | — | -2.85 ± 5.02 | — | -1.50 ± NA | -0.60 ± 1.27 |
| Change at Day 29, 1 Hour | -1.08 ± 1.22 | — | — | — | -1.57 ± 1.14 |
| Change at Day 29, 2 Hour | -1.27 ± 2.23 | — | — | — | -2.73 ± 1.85 |
| Change at Day 29, 3 Hour | -0.55 ± 1.13 | — | — | — | -3.70 ± 2.14 |
| Change at Day 29, 4 Hour | 12.03 ± 10.12 | — | — | — | -4.90 ± 1.95 |
| Change at Day 29, 6 Hour | 66.85 ± 43.07 | — | — | — | -4.17 ± 1.27 |
| Change at Day 29, 8 Hour | 135.08 ± 83.95 | — | — | — | -2.97 ± 2.20 |
| Change at Day 29, 12 Hour | 77.35 ± 43.80 | — | — | — | -2.07 ± 1.08 |
| Change at Day 29, 18 Hour | 43.80 ± 13.41 | — | — | — | -0.20 ± 1.77 |
| Change at Day 29, 24 Hour | 10.18 ± 3.16 | — | — | — | -3.07 ± 0.96 |
| Change at Day 29, 48 Hour | -5.17 ± 4.70 | — | — | — | -4.87 ± 2.24 |
| Change at Day 29, 72 Hour | -2.93 ± 3.91 | — | — | — | -1.63 ± 4.71 |
Baseline is defined as the last value obtained prior to the first dose.
| mIU/mL | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline | — | 8.30 ± 2.26 | 9.55 ± 3.32 | — | 10.45 ± 4.31 | — | — |
| Change at 4 Hour | — | 2.80 ± 3.96 | 2.10 ± 3.54 | — | 1.00 ± 2.97 | — | — |
| Change at 8 Hour | — | 66.70 ± 90.23 | 100.40 ± 92.77 | — | 42.05 ± 36.98 | — | — |
| Change at 12 Hour | — | 66.25 ± 90.16 | 147.15 ± 128.91 | — | 201.10 ± 240.42 | — | — |
| Change at 24 Hour | — | 10.05 ± 8.56 | 107.65 ± 53.25 | — | 461.05 ± 589.80 | — | — |
Collected over Baseline up to Week 16 (EoS). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat 0.7 mg/kg BIW | — | 0/10 (0%) | 3/10 (30%) |
| Roxadustat 0.7 mg/kg TIW | — | 4/13 (30.8%) | 9/13 (69.2%) |
| Roxadustat 1.0 mg/kg BIW | — | 0/12 (0%) | 7/12 (58.3%) |
| Roxadustat 1.0 mg/kg TIW | — | 0/9 (0%) | 5/9 (55.6%) |
| Roxadustat 1.5 mg/kg BIW | — | 0/10 (0%) | 9/10 (90%) |
| Roxadustat 1.5 mg/kg TIW | — | 0/11 (0%) | 7/11 (63.6%) |
| Roxadustat 2.0 mg/kg BIW | — | 0/11 (0%) | 7/11 (63.6%) |
| Roxadustat 2.0 mg/kg TIW | — | 0/12 (0%) | 5/12 (41.7%) |
| Placebo | — | 1/28 (3.6%) | 12/28 (42.9%) |
| Event | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Arteriovenous fistula siteInjury, poisoning and procedural complications | 0/10 | 1/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 0/28 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/10 | 1/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 0/28 |
| Non-cardiac chest painGeneral disorders | 0/10 | 1/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 0/28 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 1/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 0/28 |
| PericarditisCardiac disorders | 0/10 | 0/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 1/28 |
| Renal failure acuteRenal and urinary disorders | 0/10 | 0/13 | 0/12 | 0/9 | 0/10 | 0/11 | 0/11 | 0/12 | 1/28 |
| Event | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/10 | 1/13 | 0/12 | 1/9 | 3/10 | 1/11 | 0/11 | 0/12 | 1/28 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 3/13 | 2/12 | 1/9 | 1/10 | 0/11 | 1/11 | 0/12 | 2/28 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 0/13 | 0/12 | 2/9 | 1/10 | 0/11 | 1/11 | 0/12 | 1/28 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/10 | 0/13 | 0/12 | 0/9 | 2/10 | 1/11 | 0/11 | 0/12 | 0/28 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/10 | 0/13 | 0/12 | 0/9 | 0/10 | 2/11 | 0/11 | 0/12 | 0/28 |
| FatigueGeneral disorders | 0/10 | 0/13 | 1/12 | 1/9 | 0/10 | 0/11 | 2/11 | 0/12 | 0/28 |
| Renal impairmentRenal and urinary disorders | 0/10 | 0/13 | 0/12 | 0/9 | 0/10 | 2/11 | 0/11 | 0/12 | 0/28 |
| ProstatitisReproductive system and breast disorders | 0/6 | 0/6 | 0/4 | 1/6 | 0/4 | 0/1 | 0/3 | 0/3 | 0/16 |
| NauseaGastrointestinal disorders | 0/10 | 0/13 | 0/12 | 1/9 | 0/10 | 0/11 | 0/11 | 0/12 | 1/28 |
| Gastrointestinal disorderGastrointestinal disorders | 0/10 | 0/13 | 0/12 | 1/9 | 0/10 | 0/11 | 0/11 | 0/12 | 0/28 |
Part 1 and Part 2 Safety Population: Participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.6 ± 4.9 | 60.6 ± 9.2 | 69.5 ± 7.7 | 67.0 ± 8.4 | 63.8 ± 8.8 | 63.5 ± 6.4 | 64.3 ± 9.0 | 66.8 ± 7.8 | 68.6 ± 6.2 | 65.8 ± 7.8 |
| Sex: Female, Male(Participants) | Roxadustat 0.7 mg/kg BIW | Roxadustat 0.7 mg/kg TIW | Roxadustat 1.0 mg/kg BIW | Roxadustat 1.0 mg/kg TIW | Roxadustat 1.5 mg/kg BIW | Roxadustat 1.5 mg/kg TIW | Roxadustat 2.0 mg/kg BIW | Roxadustat 2.0 mg/kg TIW | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 7 | 8 | 3 | 6 | 10 | 8 | 9 | 12 | 67 |
| Male | 6 | 6 | 4 | 6 | 4 | 1 | 3 | 3 | 16 | 49 |
Ran from Nov 2006 to primary completion in Jun 2010, 43 months.
Results were first posted in Nov 2021, 11 years 4 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 43 months is above that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat
Renal Insufficiency, Chronic →